Hard Road for Medical Treatments
Only a tiny fraction of the compounds tested for different diseases ever make it to clinical trials. Now a report in Science suggests that the results of even encouraging clinical trials are later refuted with surprising frequency.
Scientists from the University of Ioannina School of Medicine in Greece analyzed published studies, from 1990 to 2004, of promising new drug candidates or medical devices. (A sampling is shown at below.) Of 32 interventions described in these papers, each of which had been cited more than 1,000 times, 13 were later shown not to work or to be less effective than originally thought.
Seven of the studies investigated new applications of well-known compounds; of these, six were later refuted. The report concludes that studies of new compounds and devices are a better use of research money.
“For common diseases, continuing to play with old agents and interventions is unlikely to give us much hope for finding some major effective intervention that we were not already aware of,” says John Ioannidis, senior author of the study.

Source: John Ioannidis
Keep Reading
Most Popular
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.